DOUBLE-BLIND, DOUBLE-CONTROLED STUDY TO COMPARE THE EFFICACY AND SAFETY OF MELOXICAM (NIFLAMIN) 15MG, AGAINST PLACEBO IN THE SYMPTOMATIC TREATMENT OF PHARMINGITIS OR FARINGO-NON-BACTERIAL ACUTE AMIGADALITIS IN A PERIOD OF 5 DAYS.
Not Applicable
- Conditions
- -J029 Acute pharyngitis, unspecifiedAcute pharyngitis, unspecifiedJ029
- Registration Number
- PER-053-02
- Lead Sponsor
- QUIMICA SUIZA S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
• Man or woman 18 years of age or older.
• Outpatient.
• Symptoms start within 24 hours.
• Patients suffering from diagnosis of pharyngitis or acute pharyngitis-tonsillitis not
bacterial
Exclusion Criteria
• Suspected pharyngitis or acute pharyngitis-tonsillitis of bacterial origin by clinical criteria
• Known or suspected hypersensitivity to the study drug or to NSAIDs.
• Examination for 13-hemolytic streptococcus in positive pharyngeal exudate.
• Therapy with antimicrobial agents prior to the start of the study.
• Chronic infections.
• Infectious mononucleosis.
• Active peptic ulcer within the previous 6 months.
• Pregnancy or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method